Company: JUNS
Filing Date: 2025-11-26
Form Type: S-1
Source: 0001493152-25-025204
Chunk: 145

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-26
Form: S-1
Chunk 145
---
by increasing lifestyle-related disorders and demand for natural ingredients. However, Nugevia faces challenges including regulatory hurdles,
complex product approvals, and competition from established players offering similar health claims. Consumer skepticism about resveratrol’s
historical bioavailability issues and the need for robust scientific validation could impact adoption. Nugevia’s use of JOTROL™
alongside ingredients like NovaSOL® Astaxanthin and CoQ10 aims to address these concerns, while strategic partnerships with Aquanova
and endorsements from figures like Annika Sörenstam and Chris Webber enhance brand trust. Success will hinge on overcoming market
saturation and proving efficacy to stand out in a crowded field.

Marketing

The Company will employ a
digital-first marketing strategy, leveraging a DTC e-commerce platform to reach health-conscious consumers seeking clinically validated
wellness solutions. The Company has appointed Annika Sörenstam, a Hall of Fame golfer with over 95 tournament victories, as Nugevia’s
first brand ambassador, enhancing brand credibility and aligning with the product’s focus on performance, focus, and longevity.
In addition, the Company has partnered with Chris Webber, five-time NBA All-Star and Hall of Fame inductee, as the Company’s second
official brand ambassador for Nugevia. Marketing efforts also include tailored campaigns for international markets, with service partners
in Hong Kong developing a specific program for Southeast Asia to address regional consumer preferences.

The initial launch in the
USA, planned for Q3 2025, will utilize a DTC model, with the Nugevia website serving as the primary sales platform. Following this, Jupiter
Neurosciences aims to expand distribution to Europe, the Middle East, and Southeast Asia through regional partnerships, capitalizing on
the global demand for longevity solutions. The Company’s strategic focus on the NLRP3 inflammasome pathway, as announced in January
2025, further underscores its commitment to addressing neuroinflammation and aging-related conditions, aligning Nugevia’s consumer
products with its broader clinical goals. By combining cutting-edge science, strategic marketing, and a robust manufacturing process,
Nugevia is poised to capture a significant share of the longevity market while supporting Jupiter’s long-term mission to advance
treatments for CNS disorders.

Competitors

The longevity and wellness
market, driven by increasing demand for health span extension, is highly competitive, with Nugevia facing established players like ChromaDex
(offering NAD+ prec